Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

992.99 +5.72 (+0.58%)
Streaming Delayed Price Updated: 2:15 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
Large Cap Biopharmaceuticals Performance
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Via Benzinga
These 2 No-Brainer Growth Stocks Are Breaking New Ground
The future keeps getting brighter for these companies. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
Via Benzinga
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
Via Benzinga
Regeneron Earnings Miss; Biotech Giant's Stock Falls
The biotech giant's earnings and sales both missed Q1 estimates. 
Via Investor's Business Daily
Week Of May 13, 2024: What's In Store For The Markets
Timeless Wisdom and timely ideas including general market commentary along with stocks to watch. 
Via Talk Markets
Healthcare And Biotech Investing 101: What You Need To Know.
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Sell In May? No Way!
Many investors and members of the financial media have been asking if it would be prudent to heed the old Wall Street adage to “sell in May and go away. 
Via Talk Markets
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. 
Via InvestorPlace
Exposures Product Safety
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
Via Benzinga
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains. 
Via InvestorPlace
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%. 
Via Benzinga
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
Via Benzinga
Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
Via Benzinga
REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
REGN stock results show that Regeneron Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
It pays to develop novel medicines for life-threatening illnesses. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent. 
Via Benzinga
2 Small-Cap Growth Stocks With Room To Run
These two small-cap growth stocks could be ready to run. 
Via The Motley Fool
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300... 
Via Benzinga
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated... 
Via Benzinga
Topics Fraud
Exposures Legal
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.